11118009

pubmed:Citation

12

To examine the effect of increased hexosamine flux in liver, the rate-limiting enzyme in hexosamine biosynthesis (glutamine:fructose-6-phosphate amidotransferase [GFA]) was overexpressed in transgenic mice using the PEPCK promoter. Liver from random-fed transgenic mice had 1.6-fold higher GFA activity compared with nontransgenic control littermates (276 +/- 24 pmol x mg(-1) x min(-1) in transgenic mice vs. 176 +/- 18 pmol x mg(-1) x min(-1) in controls, P < 0.05) and higher levels of the hexosamine end product UDP-N-acetyl glucosamine (288 +/- 11 pmol/g in transgenic mice vs. 233 +/- 10 pmol/g in controls, P < 0.001). Younger transgenic mice compared with control mice had lower fasting serum glucose (4.8 +/- 0.5 mmol/l in transgenic mice vs. 6.5 +/- 0.8 mmol/l in controls, P < 0.05) without higher insulin levels (48.0 +/- 7.8 pmol/l in transgenic mice vs. 56.4 +/- 5.4 pmol/l in controls, P = NS); insulin levels were significantly lower in transgenic males (P < 0.05). At 6 months of age, transgenic animals had normal insulin sensitivity by the hyperinsulinemic clamp technique. Hepatic glycogen content was higher in the transgenic mice (108.6 +/- 5.2 pmol/g in transgenic mice vs. 32.8 +/- 1.3 micromol/g in controls, P < 0.01), associated with an inappropriate activation of glycogen synthase. Serum levels of free fatty acids (FFAs) and triglycerides were also elevated (FFAs, 0.67 +/- 0.03 mmol/l in transgenic mice vs. 0.14 +/- 0.01 in controls; triglycerides, 1.34 +/- 0.15 mmol/l in transgenic mice vs. 0.38 +/- 0.01 in controls, P < 0.01). Older transgenic mice became heavier than control mice and exhibited relative glucose intolerance and insulin resistance. The glucose disposal rate at 8 months of age was 154 +/- 5 mg x kg(-1) x min(-1) in transgenic mice vs. 191 +/- 6 mg x kg(-1) x min(-1) in controls (P < 0.05). We conclude that hexosamines are mediators of glucose sensing for the regulation of hepatic glycogen and lipid metabolism. Increased hexosamine flux in the liver signals a shift toward fuel storage, resulting ultimately in obesity and insulin resistance.

eng

AIM

MEDLINE

0012-1797

Print

NLM

2070-8

pubmed-meshheading:11118009-Adenosine Triphosphate, pubmed-meshheading:11118009-Animals, pubmed-meshheading:11118009-Fatty Acids, Nonesterified, pubmed-meshheading:11118009-Glucosamine, pubmed-meshheading:11118009-Glucose Intolerance, pubmed-meshheading:11118009-Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing), pubmed-meshheading:11118009-Glycogen, pubmed-meshheading:11118009-Glycogen Synthase, pubmed-meshheading:11118009-Hyperlipidemias, pubmed-meshheading:11118009-Liver, pubmed-meshheading:11118009-Mice, pubmed-meshheading:11118009-Mice, Inbred C57BL, pubmed-meshheading:11118009-Mice, Transgenic, pubmed-meshheading:11118009-Obesity, pubmed-meshheading:11118009-Phosphoenolpyruvate Carboxykinase (GTP), pubmed-meshheading:11118009-Phosphorylases, pubmed-meshheading:11118009-Reference Values, pubmed-meshheading:11118009-Triglycerides, pubmed-meshheading:11118009-Uridine Diphosphate N-Acetylgalactosamine

Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance.

Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't